
ABEO
USDAbeona Therapeutics Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$4.150
高値
$4.239
安値
$4.000
出来高
0.89M
企業ファンダメンタルズ
時価総額
215.4M
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
1.15M
取引所
NCM
通貨
USD
52週レンジ
AI分析レポート
最終更新: 2025年10月31日ABEO Stock Analysis: Abeona Therapeutics Inc. - A Biotech Investment Crossroads
Recent News & Sentiment
- Key Development (Oct 30, 2025): Abeona announced a permanent J-Code for its gene therapy ZEVASKYN®, critical for enhancing reimbursement access and commercial viability. This follows months of uncertainty after the stock peaked at $7.54 (Sep 15) and crashed to $4.97 (Oct 30), shedding 34% from its 52-week high.
- Market Reaction: Despite positive news, the stock closed +1.8% on Oct 30 ($5.08 from $4.99), with volume tripling to 3.9M shares (vs. avg 970K). This suggests polarized investor sentiment - some buying on optimism, others fleeing prior losses.
Price Action Breakdown
- Three-Month Trend:
- Bullish Spike: Sharp 13.6% surge on Aug 14 ($6.77→$7.27) amid heavy volume (1.5M+ shares), hinting at speculative interest.
- Bearish Slide: Steady decline from $7.27 to $5.28 (Oct 28), followed by a sudden 5.5% dip on Oct 29 ($5.26→$4.97) - the lowest close since Jul 31.
- Critical Support Zone: Current price hovers near $5.03, the lower Bollinger Band threshold. Technical indicators conflict:
- Bullish: OBV (On-Balance Volume) surged 7.2x above average, signaling accumulation.
- Bearish: DMI confirms a downtrend (-DI 15.1 > +DI 7.7), while MACD remains below its signal line, warning of continued pressure.
Strategic Outlook
- AI Projections: Models predict +1.3% (Day 1), +1.0% (Day 2), +1.8% (Day 3), aiming for a potential $5.26 target. Confidence levels aren't specified, but the upward bias aligns with the recent J-Code catalyst.
- Valuation Contradictions:
- Positive: P/E ratio (7.9x) trails the sector's 11.9x average, and ROE (48.3%) outperforms benchmarks.
- Negative: Debt-to-Equity ratio (14.72) sits far above acceptable thresholds (threshold 0.70), raising solvency concerns.
Recommendations
1. Short-Term Tactical Buy (Neutral Bias):
- Entry Points: $5.02-$5.09 (current close at $5
関連ニュース
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the
AI予測Beta
AI推奨
更新日時: 2025年11月10日 13:08
66.0% 信頼度
リスクと取引
エントリーポイント
$4.18
利確
$4.48
損切り
$3.79
主要因子
関連株式
JKHY
Jack Henry & Associates Inc.
GPI
Group 1 Automotive Inc.
FSBW
FS Bancorp Inc.
VERO
Venus Concept Inc.
BWBBP
Bridgewater Bancshares Inc. Depositary Shares Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock Series A
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。